Bio-rad Laboratories, Inc. balance sheet
At the end of fiscal 2025, Bio-rad Laboratories, Inc. had total assets of $10.58bn, total liabilities of $3.12bn and shareholders' equity of $7.45bn. It held $530m in cash against $1.21bn of debt: net debt of $680m.
Balance sheet
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 0.6 | 0.9 | 0.6 | 0.5 | 0.3 | 0.4 | 0.5 | 0.5 | 0.4 | 0.4 | 0.7 | 0.7 | 0.5 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 |
| Receivables | — | — | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 |
| Inventory | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 |
| Total current assets | 1.6 | 2.0 | 1.8 | 1.9 | 1.8 | 1.7 | 1.8 | 1.8 | 2.0 | 2.0 | 2.2 | 2.1 | 2.0 | 3.2 | 3.0 | 3.0 | 2.9 | 3.0 |
| Goodwill | 0.3 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.2 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.6 | 0.6 |
| Total assets | 2.5 | 3.1 | 3.1 | 3.4 | 3.4 | 3.3 | 3.7 | 3.9 | 4.3 | 5.6 | 8.0 | 13.0 | 17.8 | 13.5 | 12.3 | 9.4 | 10.6 | 10.3 |
| Accounts payable | — | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Deferred revenue (current) | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 |
| Total current liabilities | 0.4 | 0.7 | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.9 | 0.6 | 0.7 | 0.6 | 0.5 | 0.5 | 0.5 | 1.0 |
| Short-term debt | 0.7 | 0.2 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-term debt | 0.7 | 0.7 | 0.7 | 0.7 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.0 | 0.0 | 0.0 | 1.2 | 1.2 | 1.2 | 1.2 | 0.8 |
| Total debt | 1.5 | 1.0 | 0.7 | 0.7 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.0 | 0.0 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 |
| Total liabilities | 1.3 | 1.5 | 1.4 | 1.4 | 1.2 | 1.2 | 1.2 | 1.3 | 1.3 | 1.6 | 2.3 | 3.1 | 4.1 | 3.9 | 3.6 | 2.8 | 3.1 | 3.1 |
| Shareholders' equity | 1.3 | 1.5 | 1.7 | 2.0 | 2.2 | 2.2 | 2.5 | 2.6 | 2.9 | 4.0 | 5.8 | 9.9 | 13.7 | 9.6 | 8.7 | 6.6 | 7.5 | 7.2 |
| Net debt (negative = net cash) | 0.8 | 0.1 | 0.2 | 0.3 | 0.1 | 0.0 | −0.0 | −0.0 | 0.1 | 0.0 | −0.2 | −0.6 | −0.5 | 0.8 | 0.8 | 0.7 | 0.7 | 0.7 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 0.5 | 0.5 | 0.4 | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 |
| Inventory | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.7 | 0.8 | 0.8 |
| Total current assets | 3.1 | 3.0 | 3.0 | 2.8 | 2.8 | 2.9 | 2.9 | 3.0 |
| Goodwill | 0.4 | 0.4 | 0.4 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 |
| Total assets | 10.6 | 9.4 | 9.5 | 10.2 | 9.7 | 10.6 | 9.8 | 10.3 |
| Accounts payable | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Deferred revenue (current) | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 |
| Total current liabilities | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.9 | 1.0 |
| Long-term debt | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 0.8 | 0.8 |
| Total debt | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 0.8 | 0.8 |
| Total liabilities | 3.1 | 2.8 | 2.8 | 3.1 | 3.0 | 3.1 | 2.9 | 3.1 |
| Shareholders' equity | 7.5 | 6.6 | 6.7 | 7.1 | 6.7 | 7.5 | 6.9 | 7.2 |
Compare with peers
- Fortrea Holdings Inc. balance sheet
- Medpace Holdings, Inc. balance sheet
- Qiagen N.V. balance sheet
- Bruker Corp balance sheet
- Charles River Laboratories balance sheet
Head to head: BIO vs FTREBIO vs MEDPBIO vs QGEN
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies